We Aim To Cure - Biomea Fusion

Biomea Fusion is a biopharmaceutical company focused on the discovery and development of covalent small molecules to cure patients with diabetes. Its lead product candidate, BMF-219, is an orally bioavailable, potent and selective covalent inhibitor of MENIN, an important transcriptional regulator known to play a direct role in beta cell regulation. Unlike currently approved diabetes treatments which are chronic therapies, BMF-219 is being studied in clinical trials as a short-term treatment to safely provide long-term glycemic control by restoring the patient’s pool of healthy beta cells.